AbbVie’s elagolix on a great roll in its PH3 trials

Clinical Trials

Clinical response was defined as menstrual blood loss volume of less than 80 mL during month six and a 50 percent or greater reduction in menstrual blood loss volume from baseline to month six. The study also met all ranked secondary endpoints (p<0.001) at month six.

AbbVie is already looking at a Q2 decision from the FDA on endometriosis, and the company looks ready to start hunting a followup approval once they gather data from the second Phase III study. AbbVie got this drug in a $575 million deal it struck in 2010 with Neurocrine $NBIX, which stands to earn a royalty payout on an approval.

AbbVie isn’t the only company in the clinic with a drug for uterine fibroids, though. Myovant $MYOV, one of the biotechs launched by Vivek Ramaswamy, is pursuing work on their own drug — relugolix — after doing a partnership with Takeda. But it will have to differentiate itself from AbbVie’s drug.

“The results from this study represent a significant advancement in the development of elagolix and demonstrate our continued commitment to address serious disease,” said Dawn Carlson, AbbVie’s vice president, general medicine development.

Subscribe to our Newsletter
Cookies make it easier for us to provide you with our services. With the usage of our services you permit us to use cookies.
More information Ok